179 related articles for article (PubMed ID: 19509478)
21. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
Yeh MW; Rougier JP; Park JW; Duh QY; Wong M; Werb Z; Clark OH
Endocr Relat Cancer; 2006 Dec; 13(4):1173-83. PubMed ID: 17158762
[TBL] [Abstract][Full Text] [Related]
22. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Ulisse S; Baldini E; Toller M; Marchioni E; Giacomelli L; De Antoni E; Ferretti E; Marzullo A; Graziano FM; Trimboli P; Biordi L; Curcio F; Gulino A; Ambesi-Impiombato FS; D'Armiento M
Eur J Cancer; 2006 Oct; 42(15):2631-8. PubMed ID: 16928445
[TBL] [Abstract][Full Text] [Related]
24. Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma.
Zhang M; Guo R; Xu H; Zhang M; Li B
Nucl Med Commun; 2011 Jul; 32(7):605-10. PubMed ID: 21471848
[TBL] [Abstract][Full Text] [Related]
25. Loss of adhesion-regulated proteinase production is correlated with invasive activity in oral squamous cell carcinoma.
Ghosh S; Munshi HG; Sen R; Linz-McGillem LA; Goldman RD; Lorch J; Green KJ; Jones JC; Stack MS
Cancer; 2002 Dec; 95(12):2524-33. PubMed ID: 12467066
[TBL] [Abstract][Full Text] [Related]
26. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.
Elisei R; Vivaldi A; Agate L; Ciampi R; Molinaro E; Piampiani P; Romei C; Faviana P; Basolo F; Miccoli P; Capodanno A; Collecchi P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2005 Apr; 90(4):2403-11. PubMed ID: 15623821
[TBL] [Abstract][Full Text] [Related]
27. Expression and secretion of endostatin in thyroid cancer.
Hoffmann S; Wunderlich A; Lingelbach S; Musholt PB; Musholt TJ; von Wasielewski R; Zielke A
Ann Surg Oncol; 2008 Dec; 15(12):3601-8. PubMed ID: 18818971
[TBL] [Abstract][Full Text] [Related]
28. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
29. Role of integrins in the attachment of metastatic follicular thyroid carcinoma cell lines to bone.
Smit JW; van der Pluijm G; Vloedgraven HJ; Löwik CW; Goslings BM
Thyroid; 1998 Jan; 8(1):29-36. PubMed ID: 9492150
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
Ragno P; Montuori N; Covelli B; Hoyer-Hansen G; Rossi G
Cancer Res; 1998 Mar; 58(6):1315-9. PubMed ID: 9515821
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Tan X; Egami H; Nozawa F; Abe M; Baba H
Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
[TBL] [Abstract][Full Text] [Related]
32. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
33. Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study.
Wang Y; Yang H; Liu H; Huang J; Song X
BMC Cancer; 2009 Jun; 9():174. PubMed ID: 19500428
[TBL] [Abstract][Full Text] [Related]
34. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.
Mohanam S; Chintala SK; Go Y; Bhattacharya A; Venkaiah B; Boyd D; Gokaslan ZL; Sawaya R; Rao JS
Oncogene; 1997 Mar; 14(11):1351-9. PubMed ID: 9178895
[TBL] [Abstract][Full Text] [Related]
35. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Mi Z; Guo H; Wai PY; Gao C; Kuo PC
Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
[TBL] [Abstract][Full Text] [Related]
36. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology.
McCaffrey JC
Laryngoscope; 2006 Jan; 116(1):1-11. PubMed ID: 16481800
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
38. PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression.
Luparello C; Sirchia R; Pupello D
J Cell Sci; 2003 Jun; 116(Pt 12):2421-30. PubMed ID: 12724357
[TBL] [Abstract][Full Text] [Related]
39. Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells.
Yuan GB; Kuang AR; Fan Q; Yu LB; Mi YX
Chin J Cancer; 2010 Apr; 29(4):379-84. PubMed ID: 20346212
[TBL] [Abstract][Full Text] [Related]
40. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
